Luminal Type B Breast Cancer Biology Character And Early Survival Analysis

[Objective] The purpose of this study was to explorer the differences betweenLuminal B breast cancer and other molecules of the clinical characteristics and theprognosis.[Methods] Ki-67, ER, PR, c-erbB-2were detected in596cases of breast cancer tissuewith Elivision immunohistochemical technique.[Results] There were no statistically significant differences among differentmolecular subtypes regarding the ages, tumor size, lymph node status, and clinicalstage. Kaplan-Meier method was used to analyze the survival prognosis of differentmolecular subtypes, showing both DFS rate and OS rate(10years) of Luminal Asubtype(93.80%、94.70%)、 Luminal B subtype(91.70%、94.90%) and theTNBC(87.20%、91.90%) were better then Her-2over-expressing subtype(81.70%、85.40%), with a statistically significant difference (P <0.05). There were nostatistically significant differences between the TNBC and Luminal B subtyperegarding prognosis. Univariate and multivariate analyses showed that moleculartyping was independent prognosis factors affecting both DFS and OS.[Conclusions] Luminal B type of breast cancer is the most number of moleculartyping, its pathological features have no statistically significant differences toothers.Luminal A subtype has best prognosis and the Her-2over-expressing has theworst, Luminal B in between. Molecular subtype is an important factor in predictingprognosis.